A phase II study of gefitinib plus S-1 after gefitinib monotherapy in patients with adenocarcinoma of the lung
Phase 2
- Conditions
- adenocarcinoma of the lung
- Registration Number
- JPRN-UMIN000006433
- Lead Sponsor
- niversity of Occupational and Environmental Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
they had a concurrent malignancy, uncontrollable complications, severe morbidity; hypersensitivity to therapeutic agents; the possibility of being pregnant, and other conditions such as hepatic inflammation, as judged by the attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS
- Secondary Outcome Measures
Name Time Method RR (gefitinib+S-1), OS, AE, and association between resistant related molecules and clinical effect